Endometriosis and Medicinal Cannabis in Australia: Symptoms, Diagnosis, and Treatment Options

Last updated: January 2026 | This article is intended for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making treatment decisions.

Overview

Endometriosis affects approximately 1 in 9 Australian women and people assigned female at birth — around 830,000 individuals — according to the Australian Government's Endometriosis in Australia strategy. Despite its prevalence, it remains one of the most under-diagnosed and poorly understood chronic conditions in the country. Patients wait an average of 6.5 to 10 years from symptom onset to confirmed diagnosis, during which time quality of life, fertility, and mental health can deteriorate significantly.

Alongside conventional treatments, there is growing interest in how medicinal cannabis — including cannabidiol (CBD) and tetrahydrocannabinol (THC) — may help manage chronic pelvic pain, inflammation, bladder symptoms, and the anxiety and depression that frequently accompany endometriosis. This guide brings together the current Australian clinical landscape, emerging research, and practical information for patients and their clinicians.

What Is Endometriosis?

Endometriosis is a chronic inflammatory condition in which tissue similar to the uterine lining (endometrium) grows outside the uterus — most commonly on the ovaries, fallopian tubes, bladder, bowel, and pelvic peritoneum. Like endometrial tissue inside the uterus, these lesions respond to hormonal fluctuations during the menstrual cycle: they thicken, break down, and bleed. Because the blood has no way to leave the body, it causes inflammation, scarring, and adhesions.

Common Symptoms

• Chronic pelvic pain, often worsening during menstruation (dysmenorrhoea)
• Pain during or after sexual intercourse (dyspareunia)
• Pain with bowel movements or urination, particularly around menstruation
• Heavy or irregular menstrual bleeding
• Bladder urgency, frequency, or interstitial cystitis-like symptoms
• Fatigue and reduced energy levels
• Infertility or difficulty conceiving (affecting around 30–50% of those with endometriosis)
• Anxiety, depression, and psychological distress linked to chronic pain burden

Symptom severity does not always correlate with disease stage. Some people with minimal visible lesions experience debilitating pain, while others with extensive disease report milder symptoms.

The Diagnosis Challenge

Endometriosis can only be definitively diagnosed through laparoscopic surgery with histological confirmation — a significant barrier to timely care. Non-invasive tools such as ultrasound and MRI can identify some manifestations (particularly endometriomas and deep infiltrating endometriosis) but cannot reliably detect all forms of the condition.

The 2023 Australian Clinical Practice Guideline for Endometriosis, published through the National Health and Medical Research Council (NHMRC), acknowledges that diagnostic delays stem from a combination of factors: symptom normalisation by both patients and clinicians, inadequate training, and a historical tendency to dismiss menstrual pain as ordinary. The guideline encourages clinicians to consider endometriosis in any person of reproductive age presenting with chronic pelvic pain and to begin empirical medical management without waiting for surgical confirmation.

Conventional Treatment Options

Treatment is tailored to symptom severity, reproductive goals, and individual response. There is currently no cure; management focuses on pain relief, hormonal suppression, and surgical intervention where necessary.

The Endocannabinoid System and Endometriosis

Interest in cannabinoid therapy for endometriosis is grounded in the biology of the endocannabinoid system (ECS) — a network of receptors (CB1 and CB2), endogenous ligands (such as anandamide), and metabolic enzymes distributed throughout the immune, nervous, and reproductive systems. Research published in journals including Human Reproduction Update and PLOS ONE has identified that the ECS plays a direct role in endometrial tissue function, pain signalling, and inflammatory cascades.

Key findings relevant to endometriosis include:

• Altered CB1/CB2 receptor expression: Studies have found that CB1 receptors are reduced in endometriotic lesions compared to healthy endometrium, which may contribute to heightened pain sensitivity and impaired natural pain regulation.
• Anandamide dysregulation: Reduced levels of anandamide (a naturally occurring endocannabinoid) have been observed in women with endometriosis, potentially impairing the body's own pain-modulating capacity.
• Nerve fibre proliferation: Endometriotic lesions are associated with abnormal sensory nerve growth; cannabinoid receptors expressed on these nerve fibres are potential targets for pain modulation.

How CBD and THC May Help: Current Evidence

Pain Management

A 2020 survey-based study by Armour et al., published in the Journal of Obstetrics and Gynaecology Canada, found that self-reported cannabis use was common among Australians with endometriosis, with participants rating it among the most effective self-management strategies for pelvic pain — outperforming many conventional options in perceived pain relief. While survey data has inherent limitations, it helped drive formal clinical interest.

THC acts primarily on CB1 receptors in the central and peripheral nervous system to modulate nociceptive signalling — the pathway by which pain signals travel from tissue to brain. CBD, which has a more complex pharmacological profile, may contribute via anti-inflammatory mechanisms, TRPV1 receptor activity, and indirect modulation of the ECS without producing intoxication.

Anti-Inflammatory Effects

Endometriosis is fundamentally an inflammatory disease. Preclinical research, including in-vitro and animal model studies, suggests that cannabinoids — particularly CBD — can reduce levels of pro-inflammatory cytokines including TNF-α, IL-6, and IL-8, which are elevated in the peritoneal fluid of people with endometriosis. A 2022 study in Frontiers in Pharmacology demonstrated that CBD reduced the invasive behaviour of endometrial cells in cell culture models, though this has not yet been replicated in clinical trials.

Bladder and Pelvic Floor Symptoms

For patients with bladder involvement or interstitial cystitis-like symptoms — a known comorbidity of endometriosis — CB2 receptors expressed in urothelial tissue represent a plausible target. Early research suggests cannabinoids may reduce bladder hypersensitivity and detrusor overactivity, though clinical evidence specific to endometriosis bladder symptoms remains limited.

Anxiety, Depression, and Sleep

Chronic pain conditions are strongly associated with psychological comorbidities. A 2021 Endometriosis Australia survey found that over 70% of respondents reported experiencing anxiety or depression. CBD has demonstrated anxiolytic properties in clinical trials for other anxiety disorders, and some THC-containing products may support sleep onset and quality. Prescribing clinicians will typically consider the risk-benefit profile carefully, particularly with higher-THC formulations in patients with mental health histories.

Accessing Medicinal Cannabis for Endometriosis in Australia

Medicinal cannabis is legal in Australia under the Therapeutic Goods Administration (TGA) framework. It is not available over the counter and must be prescribed by a registered medical practitioner. Most medicinal cannabis products for endometriosis are accessed via the Special Access Scheme Category B (SAS-B) or through an Authorised Prescriber.

Endometriosis is not a TGA-registered indication for any currently listed cannabis medicine in Australia, meaning prescriptions are made on an unapproved medicine basis — a common pathway used for many chronic pain and inflammatory conditions. Clinicians document clinical justification and patient consent before prescribing.

Typical Prescribing Patterns

• CBD-dominant oils: Often trialled first for patients with inflammatory pain, anxiety, or sleep disturbance; low risk of psychoactive effects
• Balanced CBD:THC formulations: May be considered where CBD alone provides insufficient analgesia
• THC-dominant products: Generally reserved for patients with moderate-to-severe breakthrough pain unresponsive to other treatments; requires careful titration
• Delivery routes: Oral oils are most common; inhalation via vaporiser is used by some patients for faster onset but carries respiratory considerations

State and Territory Considerations

While the TGA governs federal approval, some Australian states and territories have additional requirements around prescribing or dispensing. Patients in rural and remote areas may access telehealth medicinal cannabis clinics. Driving laws across all Australian jurisdictions currently prohibit driving with any detectable THC in oral fluid, regardless of impairment — a critical consideration for patients prescribed THC-containing products. Patients should discuss this explicitly with their prescribing clinician.

Talking to Your Doctor

If you are living with endometriosis and considering medicinal cannabis as part of your management plan, the following steps are recommended by integrative medicine specialists and gynaecologists experienced in this area:

• Raise it openly with your GP or specialist — medicinal cannabis is a legal, regulated option and should be part of a shared decision-making conversation
• Bring a symptom diary that documents pain scores, menstrual cycle timing, sleep, and mood to support clinical assessment
• Ask for a referral to a clinician experienced in cannabinoid medicine if your current provider is unfamiliar with prescribing pathways
• Discuss any medications you currently take, as CBD in particular can interact with drugs metabolised by the CYP450 enzyme system, including some anticoagulants and anticonvulsants
• Understand that medicinal cannabis is one component of a broader management plan and is most effective when combined with other evidence-based care

Key Takeaways

• Endometriosis affects approximately 1 in 9 Australians and carries an average diagnostic delay of 6.5–10 years
• The endocannabinoid system plays a documented role in endometrial biology, pain regulation, and inflammation
• Emerging clinical and preclinical evidence supports cannabinoids as a potentially useful adjunct for pelvic pain, inflammation, bladder symptoms, and psychological comorbidities
• Medicinal cannabis is legally accessible in Australia via TGA pathways but requires a prescription and should be managed by a clinician experienced in both endometriosis and cannabinoid medicine
• Driving with detectable THC is illegal across all Australian states and territories regardless of prescription status
• No treatment offers a cure; the goal is improved quality of life through individualised, evidence-informed care

Sources

• NHMRC – Australian Clinical Practice Guideline for Endometriosis
• Australian Government Department of Health and Aged Care – Endometriosis
• Therapeutic Goods Administration – Medicinal Cannabis Hub
• Endometriosis Australia – Patient resources and research updates
• Armour M et al. (2019) – Self-management strategies for endometriosis, JOGC (PubMed)
• Bouaziz J et al. (2019) – The Clinical Significance of Endocannabinoids in Endometriosis Pain Management, Cannabis and Cannabinoid Research (PubMed)
• Sanchez AM et al. (2012) – The endocannabinoid system in the endometrium, Molecular Human Reproduction (PubMed)
• RACGP – Prescribing Medicinal Cannabis: Clinical Guidance